Vol 6, No 2 (April 27, 2017): Translational Lung Cancer Research (Combining Radiation Therapy and Immunotherapy for Thoracic Malignancies)1

Preface

Harnessing the potential synergy of combining radiation therapy and immunotherapy for thoracic malignancies
Charles B. Simone II, Abigail T. Berman, Salma K. Jabbour
Translational Lung Cancer Research  
2017;
6
(2)
:109-112
.

Review Article

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer
Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II
Translational Lung Cancer Research  
2017;
6
(2)
:113-118
.
Special topics in immunotherapy and radiation therapy: reirradiation and palliation
Tracey Evans, Christine Ciunci, Lauren Hertan, Daniel Gomez
Translational Lung Cancer Research  
2017;
6
(2)
:119-130
.
Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy
Tejan P. Diwanji, Pranshu Mohindra, Melissa Vyfhuis, James W. Snider III, Chaitanya Kalavagunta, Sina Mossahebi, Jen Yu, Steven Feigenberg, Shahed N. Badiyan
Translational Lung Cancer Research  
2017;
6
(2)
:131-147
.
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation
Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh
Translational Lung Cancer Research  
2017;
6
(2)
:148-158
.
Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART)
James P. Flynn, Mark H. O’Hara, Saumil J. Gandhi
Translational Lung Cancer Research  
2017;
6
(2)
:159-168
.
Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma
Anusha Kalbasi, Ramesh Rengan
Translational Lung Cancer Research  
2017;
6
(2)
:169-177
.
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer
Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft
Translational Lung Cancer Research  
2017;
6
(2)
:178-185
.
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors
Suchit H. Patel, Andreas Rimner, Roger B. Cohen
Translational Lung Cancer Research  
2017;
6
(2)
:186-195
.
Current state of immunotherapy for non-small cell lung cancer
Jyoti Malhotra, Salma K. Jabbour, Joseph Aisner
Translational Lung Cancer Research  
2017;
6
(2)
:196-211
.
Immunotherapy and radiation therapy for malignant pleural mesothelioma
Evan W. Alley, Sharyn I. Katz, Keith A. Cengel, Charles B. Simone II
Translational Lung Cancer Research  
2017;
6
(2)
:212-219
.

Mini-Review

Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer
Allison M. Campbell, Roy H. Decker
Translational Lung Cancer Research  
2017;
6
(2)
:220-229
.

Controversies on Lung Cancer: Pros and Cons2

Pros: the present classification of mucinous adenocarcinomas of the lung
Sanja Dacic
Translational Lung Cancer Research  
2017;
6
(2)
:230-233
.
Cons: the confusing mucinous adenocarcinoma classification
Helmut H. Popper
Translational Lung Cancer Research  
2017;
6
(2)
:234-240
.
Rebuttal from Professor Sanja Dacic
Sanja Dacic
Translational Lung Cancer Research  
2017;
6
(2)
:241-242
.
Rebuttal from Professor Helmut H. Popper
Helmut H. Popper
Translational Lung Cancer Research  
2017;
6
(2)
:243-245
.

Disclosure:

1. The focused issue “Combining Radiation Therapy and Immunotherapy for Thoracic Malignancies” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. Charles B. Simone II, Abigail T. Berman and Salma K. Jabbour served as the unpaid Guest Editors for the focused issue.

2. The series “Controversies on Lung Cancer: Pros and Cons” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Suresh Senan and Helmut H. Popper served as the unpaid Guest Editors for the series.